5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town


Reports from the conference

For the first time, web casts of several sessions are available via the conference website together with searchable online abstracts and PDF files of many or the posters or presentations

The abstract database from the meeting is online at the same site.

In this issue we include the following articles:

  • Overview of ARV studies at IAS
    • First results of new integrase compound: GSK1349572
    • Raltegravir in treatment naive-patients
    • Nevirapine vs atazanavir/ritonavir in treatment-naive patients: the ARTEN study
    • Darunavir/r monotherapy studies
    • Maraviroc results similar to efavirenz when analysed using more sensitive tropism test
  • Lipid and metabolic changes with ARV combinations
  • Maximal suppression achieved with three drugs: no additional virological impact of raltegravir intensification
  • Tenofovir and renal safety
  • Time from seroconversion to treatment in Europe and Africa
  • Pharmacokinetics of atazanavir/ritonavir during pregnancy
  • Presentation with late stage HIV in women diagnosed during pregnancy
  • Low transmission rates and favourable pregnancy outcomes reported in the DREAM study
  • Pregnancy rates and outcomes among women in the DART trial
  • Pregnancy outcomes in HAART exposed infants in Johannesburg
  • Efavirenz conceptions in Soweto
  • Impact of regimen and duration of therapy on risk of mother-to-child HIV transmission in Johannesburg
  • A cost-effectiveness analysis of the OCTANE trial
  • The PEARL study
  • Results from HSV-2 acyclovir studies
  • Overview of TB-related studies at IAS

Links to other websites are current at date of posting but not maintained.